In case of NSCLC, PET imaging with [64Cu]Cu-DOTA-cetuximab by itself could predict the response to therapy as it is indicative of cetuximab tumor accessibility while the therapeutic response are not associated with biomolecular characteristics such as the status of KRAS, PTEN, and EGFR mutations. Here, PTEN is linked to neoplasm.